Does race make a difference in how long men with advanced prostate cancer live when treated with abiraterone or enzalutamide?

Daniel J George,Krishnan Ramaswamy,Ahong Huang,David Russell,Neil M Schultz,Nora Janjan,Stephen J Freedland

Future oncology (London, England)（2022）

引用 0|浏览10

暂无评分

摘要

This real-world, US study of men with mCRPC treated with abiraterone or enzalutamide found that Black men lived longer than White men. All men in this study had equal access to healthcare and were treated with either abiraterone or enzalutamide. More research is needed to understand the reasons for this. Understanding these reasons could guide treatment to help men with mCRPC live longer.

查看译文

关键词

abiraterone,advanced prostate cancer,enzalutamide,lay summary,metastatic castration-resistant prostate cancer,plain language summary,race,real world,veterans health administration

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要